Editas signs genome-edited stem cell pact with GSK, Biogen biotech partner – FierceBiotech
FierceBiotech |
Editas signs genome-edited stem cell pact with GSK, Biogen biotech partner
FierceBiotech Gene editing biotech Editas Medicine ($EDIT) has signed a three-year R&D collab deal with Milanese-based San Raffaele Telethon Institute for Gene Therapy to develop next-gen stem and T-cell therapies. The Italian Institute (also known as … Editas, SR-TIGET Launch Research Collaboration |
